In an in-vitro model, the combination of r-hirudin and DX9065a demonstrated complementary inhibition of both clot-bound thrombin and clot-bound factor Xa, unlike heparins.
Does the combination of direct thrombin and factor Xa inhibitors improve the inhibition of clot-associated procoagulant activity compared to individual agents or heparins in an in-vitro model?
The combination of direct thrombin and factor Xa inhibitors provides complementary inhibition of clot-associated procoagulant activity in vitro, suggesting a potential strategy for treating acute arterial thrombosis.
The procoagulant activity of a thrombus is essentially due to clot-associated factor IIa and factor Xa activities.The aim of this review is to underline that specific antithrombin and anti-Xa drugs, such as r-hirudin and DX 9065a, respectively, are complementary, and could be used in combination in clinical trials in patients with acute arterial thrombosis such as coronary syndromes. After standardization of the in-vitro techniques for clot-bound thrombin and clot-associated factor Xa, we have studied the anticoagulant effect of unfractionated heparin and a low-molecular heparin in an in-vitro model. We have confirmed the inability of heparins to inhibit clot-bound thrombin and clot-associated factor Xa. We have compared r-hirudin, a direct thrombin inhibitor, with DX9065a, a direct factor Xa inhibitor. We have observed that r-hirudin inhibited clot-bound thrombin but not clot-bound factor Xa. After r-hirudin treatment interruption, a hypercoagulation rebound has been reported and it could be in relation with the persistence of factor Xa activity in the clot. We have demonstrated that DX9065a inhibits clot-bound factor Xa but does not inhibit clot-bound factor IIa. The complementary effect of DX9065a and r-hirudin is demonstrated in this experimental model. It is likely that several other combinations of drugs may also exhibit an increase of the antithrombotic activity which could be of interest in clinical implication for the treatment of several groups of patients at high risk of arterial thrombosis.
Meddahi et al. (Wed,) conducted a review in Acute arterial thrombosis. Combination of r-hirudin and DX9065a vs. Heparins or individual agents was evaluated on Inhibition of clot-bound thrombin and clot-associated factor Xa. In an in-vitro model, the combination of r-hirudin and DX9065a demonstrated complementary inhibition of both clot-bound thrombin and clot-bound factor Xa, unlike heparins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: